サンプル依頼リスト カート
  • English
  • Korean
表紙：ウイルス性肝炎の世界市場レポート 2024年
市場調査レポート
商品コード
1415775

ウイルス性肝炎の世界市場レポート 2024年

Viral Hepatitis Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ウイルス性肝炎の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ウイルス性肝炎市場規模は近年着実に成長しています。2023年の154億8,000万米ドルから2024年には162億1,000万米ドルへとCAGR4.7％で拡大します。歴史的な期間の成長は、ワクチン開発、血液スクリーニングプログラム、抗ウイルス薬、世界ヘルスイニシアチブに起因しています。

ウイルス性肝炎の市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR4.1％で190億1,000万米ドルに成長します。予測期間の成長は、治療へのアクセス、公衆衛生法、併用療法、健康公平性への取り組みに起因すると考えられます。予測期間における主な動向には、個別化治療計画、デジタルヘルスツール、疾患モニタリングにおけるai、c型肝炎の微小排除などがあります。

肝炎の有病率の高まりは、近い将来、ウイルス性肝炎市場拡大のカタリストとして機能する準備が整っています。肝炎は、肝臓の炎症と損傷を特徴とする疾患で、さまざまな感染性ウイルスや非感染性薬剤によって引き起こされ、さまざまな医学的合併症を引き起こします。ウイルス性肝炎の原因となるウイルスの中には、A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎があります。例えば、2023年8月現在、米国の国立公衆衛生機関である疾病対策予防センター（Centers for Disease Control and Prevention）は、米国では2020年に49州とコロンビア特別区で約9,952件のA型肝炎患者が発生したと報告しています。さらに、2020年には44州から4,798件のC型急性肝炎の症例がCDCに報告され、41州では合わせて107,300件のC型慢性肝炎の新規診断症例が同年にCDCに報告されました。このように、肝炎の急増がウイルス性肝炎市場の成長促進要因となっています。

ウイルス性肝炎市場の強力な成長要因として、研究開発（R&D）の増加が期待されています。ウイルス性肝炎に焦点を当てた研究開発活動は、ワクチン、抗ウイルス薬、診断検査、疫学調査、公衆衛生介入、ゲノム研究、予防戦略、世界ヘルスキャンペーン、臨床試験、および同時感染症の調査などの開発を含む幅広い活動を包含しています。研究開発活動の活発化は、治療アプローチの革新を促進するだけでなく、診断や予防の選択肢を広げます。その結果、臨床試験の数が増え、世界ヘルスへの取り組みが強化され、製薬企業間の競争が激化します。例えば、2022年11月、メルボルンの研究者たちは、mRNAビクトリア活性化プログラムを通じて、今後5年間で170万米ドルの資金を確保しました。この資金提供により、B型肝炎ウイルス感染の治療法を求める先駆的な研究が前進することになります。その結果、研究開発活動の活発化がウイルス性肝炎市場成長の原動力となっています。

2023年のウイルス性肝炎市場で最大の地域は北米でした。ウイルス性肝炎レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のウイルス性肝炎市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • A型肝炎
  • B型肝炎
  • C型肝炎
  • その他
  • 世界のウイルス性肝炎市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肝生検
  • 血液検査
  • 画像検査
  • その他
  • 世界のウイルス性肝炎市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗ウイルス薬
  • 手術
  • ワクチン
  • 免疫調節薬
  • その他
  • 世界のウイルス性肝炎市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界のウイルス性肝炎市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • 在宅ケア
  • その他

第7章 地域および国の分析

  • 世界のウイルス性肝炎市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のウイルス性肝炎市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ウイルス性肝炎市場の競合情勢
  • ウイルス性肝炎市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Co
    • F Hoffmann-La Roche AG
    • Merck &Co.
    • AbbVie Inc.

第31章 その他の主要および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb
  • Astra Zeneca Pharmaceuticals LP
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Co. Ltd.
  • Hetero Drugs Ltd.
  • Eisai Co. Ltd.
  • Boehringer Ingelheim Group
  • Sun Pharmaceutical Industries Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12374

“Viral Hepatitis Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral hepatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral hepatitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The viral hepatitis market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
  • 2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
  • 3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
  • 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
  • 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Co; F Hoffmann-La Roche AG; Merck & Co.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.

The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.

The viral hepatitis market research report is one of a series of new reports from The Business Research Company that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral hepatitis market size has grown steadily in recent years. It will grow from $15.48 billion in 2023 to $16.21 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.01 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

The heightened prevalence of hepatitis is poised to act as a catalyst for the expansion of the viral hepatitis market in the near future. Hepatitis, a condition characterized by liver inflammation and damage, can be caused by various infectious viruses and non-infectious agents, leading to a spectrum of medical complications. Among the viruses responsible for viral hepatitis are hepatitis A, B, C, D, and E. For instance, as of August 2023, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that in the United States, there were approximately 9,952 cases of hepatitis A across 49 states and the District of Columbia in the year 2020. Additionally, 4,798 cases of acute hepatitis C were reported to the CDC from 44 states in 2020, and 41 states collectively reported a total of 107,300 newly diagnosed cases of chronic hepatitis C to the CDC in the same year. Thus, the surging prevalence of hepatitis is set to be a key driver of growth in the viral hepatitis market.

The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.

The growth of the viral hepatitis market during the forecast period is impeded by the substantial costs associated with treatments. The elevated treatment costs for viral hepatitis have the potential to create obstacles in the realm of prevention, diagnosis, and therapeutic efforts. Such costs can result in restricted access to care, generate financial burdens for individuals and healthcare systems, and contribute to health disparities on both national and global scales. For instance, data from 2022, sourced from the National Library of Medicine, a biomedical library, indicated a range in the cost of antiviral drugs for hepatitis B and C, with annual expenses varying from $10 to $36, while annual monitoring carried an approximate cost of $38 per year. Consequently, the high treatment costs are acting as a hindrance to the viral hepatitis market's growth.

Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.

In March 2021, Gilead Sciences Inc., a US-based biopharmaceutical company, completed its acquisition of MYR GmbH for an approximate sum of $1.60 billion (€1.45 billion). This acquisition enabled Gilead to obtain Hepcludex (bulevirtide), provisionally licensed by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in individuals with compensated liver disease. MYR GmbH, headquartered in Germany, specializes in the development and manufacturing of treatments for chronic hepatitis B and D viral diseases.

Major players in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd. .

North America was the largest region in the viral hepatitis market in 2023. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Viral Hepatitis Market Characteristics

3. Viral Hepatitis Market Trends And Strategies

4. Viral Hepatitis Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Viral Hepatitis Market Size and Growth

  • 5.1. Global Viral Hepatitis Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Viral Hepatitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Viral Hepatitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Viral Hepatitis Market Segmentation

  • 6.1. Global Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Other Disease Types
  • 6.2. Global Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Liver Biopsy
  • Blood Tests
  • Imaging Tests
  • Other Diagnosis
  • 6.3. Global Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antiviral Drugs
  • Surgery
  • Vaccine
  • Immune Modulator Drugs
  • Other Treatments
  • 6.4. Global Viral Hepatitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes Of Administration
  • 6.5. Global Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users

7. Viral Hepatitis Market Regional And Country Analysis

  • 7.1. Global Viral Hepatitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Viral Hepatitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Viral Hepatitis Market

  • 8.1. Asia-Pacific Viral Hepatitis Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Viral Hepatitis Market

  • 9.1. China Viral Hepatitis Market Overview
  • 9.2. China Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Viral Hepatitis Market

  • 10.1. India Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Viral Hepatitis Market

  • 11.1. Japan Viral Hepatitis Market Overview
  • 11.2. Japan Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Viral Hepatitis Market

  • 12.1. Australia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Viral Hepatitis Market

  • 13.1. Indonesia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Viral Hepatitis Market

  • 14.1. South Korea Viral Hepatitis Market Overview
  • 14.2. South Korea Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Viral Hepatitis Market

  • 15.1. Western Europe Viral Hepatitis Market Overview
  • 15.2. Western Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Viral Hepatitis Market

  • 16.1. UK Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Viral Hepatitis Market

  • 17.1. Germany Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Viral Hepatitis Market

  • 18.1. France Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Viral Hepatitis Market

  • 19.1. Italy Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Viral Hepatitis Market

  • 20.1. Spain Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Viral Hepatitis Market

  • 21.1. Eastern Europe Viral Hepatitis Market Overview
  • 21.2. Eastern Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Viral Hepatitis Market

  • 22.1. Russia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Viral Hepatitis Market

  • 23.1. North America Viral Hepatitis Market Overview
  • 23.2. North America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Viral Hepatitis Market

  • 24.1. USA Viral Hepatitis Market Overview
  • 24.2. USA Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Viral Hepatitis Market

  • 25.1. Canada Viral Hepatitis Market Overview
  • 25.2. Canada Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Viral Hepatitis Market

  • 26.1. South America Viral Hepatitis Market Overview
  • 26.2. South America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Viral Hepatitis Market

  • 27.1. Brazil Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Viral Hepatitis Market

  • 28.1. Middle East Viral Hepatitis Market Overview
  • 28.2. Middle East Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Viral Hepatitis Market

  • 29.1. Africa Viral Hepatitis Market Overview
  • 29.2. Africa Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Viral Hepatitis Market Competitive Landscape And Company Profiles

  • 30.1. Viral Hepatitis Market Competitive Landscape
  • 30.2. Viral Hepatitis Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Co
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Viral Hepatitis Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi SA
  • 31.3. Bristol-Myers Squibb
  • 31.4. Astra Zeneca Pharmaceuticals LP
  • 31.5. GlaxoSmithKline plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Gilead Sciences Inc.
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Astellas Pharma Inc.
  • 31.11. Daiichi Sankyo Co. Ltd.
  • 31.12. Hetero Drugs Ltd.
  • 31.13. Eisai Co. Ltd.
  • 31.14. Boehringer Ingelheim Group
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Viral Hepatitis Market Competitive Benchmarking

33. Global Viral Hepatitis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Viral Hepatitis Market

35. Viral Hepatitis Market Future Outlook and Potential Analysis

  • 35.1 Viral Hepatitis Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Viral Hepatitis Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Viral Hepatitis Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer